Mayne Pharma Group Ltd (MYX)

Currency in AUD
5.740
+2.530(+78.82%)
Delayed Data·
Unusual trading volume
Earnings results expected in 0 days
MYX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.7005.970
52 wk Range
2.0406.040
Key Statistics
Bid/Ask
5.74 / 5.76
Prev. Close
3.21
Open
5.76
Day's Range
5.7-5.97
52 wk Range
2.04-6.04
Volume
820.79K
Average Volume (3m)
232.09K
1-Year Change
18.3505%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MYX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.397
Downside
-23.40%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Mayne Pharma Group Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.397
(-23.40% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy3.65-36.30%3.75Maintain26/10/2026
Canaccord
Buy3.75-34.55%3.83Maintain28/08/2026
Canaccord
Buy3.83-33.16%6.10Downgrade02/07/2026

Mayne Pharma Group Ltd Earnings Call Summary for H2/2026

  • Mayne Pharma reported FY2026 revenue of AUD 383.7M (down 6%), but gross margin expanded 411 bps to 64.7% on improved product mix and pricing.
  • Underlying EBITDA fell 27% to AUD 34.2M due to higher sales/marketing spend, FX headwinds, and litigation costs from Cosette dispute.
  • Women's health products BIJUVA, IMVEXXY, and NEXTSTELLIS grew; new distribution platform DistributeRx added 5,000 prescribers, expanding capacity.
  • Management expects FY2027 margin improvement from women's health growth, reduced one-off costs, and resolution of ANNOVERA product returns.
  • Stock unchanged at $3.17; company remains unprofitable with cash position declining to AUD 80M from AUD 100.4M year-over-year.
Last Updated: 27/08/2026, 10:24 am
Read Full Transcript

Earnings

Latest Release
25/10/2026
EPS / Forecast
-- / --
Revenue / Forecast
95.7M / --
EPS Revisions
Last 90 days

MYX Income Statement

Compare MYX to Peers and Sector

Metrics to compare
MYX
Peers
Sector
Relationship
P/E Ratio
8.5x14.9x−0.2x
PEG Ratio
0.070.100.00
Price/Book
0.7x3.1x2.6x
Price / LTM Sales
0.7x3.1x2.8x
Upside (Analyst Target)
37.0%39.5%65.0%
Fair Value Upside
Unlock27.7%9.5%Unlock

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Employees
363
Market
Australia

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.13M7.48%20.22M
Other Institutional Investors
58.48M71.42%193.00M
Public Companies & Retail Investors
17.28M21.10%57.02M
Total
81.89M100.00%270.24M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Funicular Fund, LP9.82%8,045,34926,550
Cable Car Capital LLC9.82%8,045,34926,550

FAQ

What Is the Mayne Pharma (MYX) Stock Price Today?

The Mayne Pharma stock price today is 5.740 AUD.

What Stock Exchange Does Mayne Pharma Trade On?

Mayne Pharma is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Mayne Pharma?

The stock symbol for Mayne Pharma is "MYX."

What Is the Mayne Pharma Market Cap?

As of today, Mayne Pharma market cap is 470.050M AUD.

What Is Mayne Pharma's Earnings Per Share (TTM)?

The Mayne Pharma EPS (TTM) is 0.39.

From a Technical Analysis Perspective, Is MYX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Mayne Pharma Stock Split?

Mayne Pharma has split 4 times.

How Many Employees Does Mayne Pharma Have?

Mayne Pharma has 363 employees.

What is the current trading status of Mayne Pharma (MYX)?

As of 16/11/2026, Mayne Pharma (MYX) is trading at a price of 5.740 AUD, with a previous close of 3.210 AUD. The stock has fluctuated within a day range of 5.700 AUD to 5.970 AUD, while its 52-week range spans from 2.040 AUD to 6.040 AUD.

What Is Mayne Pharma (MYX) Price Target According to Analysts?

The average 12-month price target for Mayne Pharma is 4.397 AUD, with a high estimate of 5.34 AUD and a low estimate of 3.65 AUD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -23.40% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.